July 11, 2017

Morphotek Announces Publication Uncovering One of the Mechanisms by Which the Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
Read More

April 26, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 13th Annual PEGS Summit in Boston
Read More

April 3, 2017

Morphotek Launches Antibody Drug Conjugate Services Business
Read More

News & Events > News Archive > 2017 News